Active Ingredient History

  • Now
Foretinib is an experimental drug candidate for the treatment of cancer. It was discovered by Exelixis and is under development by GlaxoSmithKline. About 10 Phase II clinical trials have been run. As of October 2015 it appears development has been discontinued.   Wikipedia

  • SMILES: COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3F)ccnc2cc1OCCCN6CCOCC6
  • Mol. Mass: 632.66
  • ALogP: 5.77
  • ChEMBL Molecule:
More Chemistry
exel 2880 | exel-2880 | foretinib | gsk089 | gsk1363089 | gsk 1363089 | gsk-1363089 | gsk1363089g | xl 880 | xl-880 | xl880 cpd


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue